Acadia Pharmaceuticals | ACAD - 净收入



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 3.51B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


净收入 更改 日
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
ALKERMES USD -66.48M 115.82M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Cara Therapeutics USD -5.53M 621K 2025-09
Corcept Therapeutics USD -31.76M 56.05M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
Eisai JPY -3.25B 20.43B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Incyte USD 303.33M 4.05M 2026-03
J&J USD 5.24B 119M 2026-03
Moderna USD -1.34B 517M 2026-03
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
Prothena USD -21.59M 14.95M 2025-12
PTC Therapeutics USD -2.81M 132.16M 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03